nab1-paclitaxel (Abraxane) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC): An International, Open-label, Multi-center, Phase 2 Study (LAPACT).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Capecitabine (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms LAPACT
- Sponsors Celgene Corporation
- 28 Sep 2017 Planned primary completion date changed from 1 Jun 2018 to 16 Oct 2017.
- 12 Sep 2017 Interim results (n=101) related to health related quality of life (QoL), presented at the 42nd European Society for Medical Oncology Congress.
- 12 Sep 2017 Interim results (n=101) presented at the 42nd European Society for Medical Oncology Congress
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History